We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Sensor Test Indicates Early Inflammation in Oral Cavity

By LabMedica International staff writers
Posted on 28 Aug 2017
Researchers have developed a novel rapid test using chewing gum and the tongue as a 24/7 detector, potentially providing a diagnostic device that could be used by nearly “anyone, anywhere, anytime”. More...
Their first such gum was successful in using saliva samples to identify patients with dental implants who had early-stage inflammation due to bacterial infection. Expanding this platform technology to other diseases could also provide more efficient screening of large populations.

Dental implants occasionally entail complications: in the years after receiving an implant 6-15% of patients develop an inflammatory response caused by bacteria, in the worst case destroying the soft tissue and bone around the implant. When the new test will be available (planned for in 2-3 years), patients would benefit from a simple, quick, and affordable method to assess whether they carry such bacteria.

The gum test was developed by a pharmaceutical research team at Julius-Maximilians-University Würzburg (JMU, Wurzburg, Germany) to provide early detection aimed at preventing serious complications. "Anyone can use this new diagnostic tool anywhere and anytime without any technical equipment," said Prof. Lorenz Meinel of JMU, who co-led the development with Dr. Jennifer Ritzer. Initial proof-of-principle studies using saliva of patients were conducted at Merli Dental Clinic in Rimini.

The scientific background: In the presence of inflammatory conditions, specific protein-degrading enzymes (matrix metalloproteinases) are activated in the mouth. While chewing the gum, these enzymes also rapidly break down the special ingredient in gum: peptide sensors consisting of a protease cleavable linker in between a bitter substance and a microparticle. When the peptide is cleaved, the bitter tasting substance is released and detected by the tongue. Patients can then visit their dentist who confirms the diagnosis and treats the disease.

Chewing gum rapid tests for other medical applications are presently under development. "We hope to be able to diagnose other diseases with our “anyone, anywhere, anytime” diagnostics to identify and address these diseases as early as possible," said Prof. Meinel.

The study, by Ritzer J et al, was published August 15, 2017, in the journal Nature Communications.

Related Links:
Julius-Maximilians-University Würzburg


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.